Click on a filter below to refine your search. Remove a filter to broaden your search.
In New England and the Pacific, prevalence tended to be lower, whereas higher prevalence was seen in the South, Midwest and West.
The greatest increase in utilization was seen for veterans aged 85 years and older (6.1 visits) versus those aged 20 to 44 years (4.8 visits).
The findings were clinically significant at three and 12 months versus usual care.
Vaccine effectiveness was 49% at 60 to 119 days after vaccination among tests exhibiting spike gene target failure.
No reason other than mild symptoms was given for almost half of patients at high risk for progression who were not offered treatment.